TY - JOUR
T1 - Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer
AU - Liu, Wennuan
AU - Lindberg, Johan
AU - Sui, G.
AU - Luo, J.
AU - Egevad, Lars
AU - Li, Tao
AU - Xie, Chunmei C.
AU - Wan, M.
AU - Kim, Seongtae
AU - Wang, Zhong
AU - Turner, Aubrey R.
AU - Zhang, Zheng
AU - Feng, Junjie
AU - Yan, Y.
AU - Sun, Jishan
AU - Bova, G. Steven
AU - Ewing, C. M.
AU - Yan, G.
AU - Gielzak, M.
AU - Cramer, Scott D.
AU - Vessella, R. L.
AU - Zheng, S. Lilly
AU - Grönberg, Henrik
AU - Isaacs, William B.
AU - Xu, Jianfeng
PY - 2012/8/30
Y1 - 2012/8/30
N2 - A clearer definition of the molecular determinants that drive the development and progression of prostate cancer (PCa) is urgently needed. Efforts to map recurrent somatic deletions in the tumor genome, especially homozygous deletions (HODs), have provided important positional information in the search for cancer-causing genes. Analyzing HODs in the tumors of 244 patients from two independent cohorts and 22 PCa xenografts using high-resolution single-nucleotide polymorphism arrays, herein we report the identification of CHD1, a chromatin remodeler, as one of the most frequently homozygously deleted genes in PCa, second only to PTEN in this regard. The HODs observed in CHD1, including deletions affecting only internal exons of CHD1, were found to completely extinguish the expression of mRNA of this gene in PCa xenografts. Loss of this chromatin remodeler in clinical specimens is significantly associated with an increased number of additional chromosomal deletions, both hemi-and homozygous, especially on 2q, 5q and 6q. Together with the deletions observed in HEK293 cells stably transfected with CHD1 small hairpin RNA, these data suggest a causal relationship. Downregulation of Chd1 in mouse prostate epithelial cells caused dramatic morphological changes indicative of increased invasiveness, but did not result in transformation. Indicating a new role of CHD1, these findings collectively suggest that distinct CHD1-associated alterations of genomic structure evolve during and are required for the development of PCa. © 2012 Macmillan Publishers Limited. All rights reserved.
AB - A clearer definition of the molecular determinants that drive the development and progression of prostate cancer (PCa) is urgently needed. Efforts to map recurrent somatic deletions in the tumor genome, especially homozygous deletions (HODs), have provided important positional information in the search for cancer-causing genes. Analyzing HODs in the tumors of 244 patients from two independent cohorts and 22 PCa xenografts using high-resolution single-nucleotide polymorphism arrays, herein we report the identification of CHD1, a chromatin remodeler, as one of the most frequently homozygously deleted genes in PCa, second only to PTEN in this regard. The HODs observed in CHD1, including deletions affecting only internal exons of CHD1, were found to completely extinguish the expression of mRNA of this gene in PCa xenografts. Loss of this chromatin remodeler in clinical specimens is significantly associated with an increased number of additional chromosomal deletions, both hemi-and homozygous, especially on 2q, 5q and 6q. Together with the deletions observed in HEK293 cells stably transfected with CHD1 small hairpin RNA, these data suggest a causal relationship. Downregulation of Chd1 in mouse prostate epithelial cells caused dramatic morphological changes indicative of increased invasiveness, but did not result in transformation. Indicating a new role of CHD1, these findings collectively suggest that distinct CHD1-associated alterations of genomic structure evolve during and are required for the development of PCa. © 2012 Macmillan Publishers Limited. All rights reserved.
KW - CHD1
KW - homozygous deletion
KW - prostate cancer
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84865639773&origin=inward
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84865639773&origin=inward
U2 - 10.1038/onc.2011.554
DO - 10.1038/onc.2011.554
M3 - Article
C2 - 22139082
SN - 0950-9232
VL - 31
SP - 3939
EP - 3948
JO - Oncogene
JF - Oncogene
IS - 35
ER -